Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Voltage-gated potassium channel subunit Kv3.2 (encoded by KCNC2) is a tetrameric transmembrane protein forming potassium-selective pores in neuronal membranes. Kv3.2 channels are members of the Kv3 subfamily (including Kv3.1, Kv3.2, Kv3.3, Kv3.4), distinguished by their high activation threshold and rapid gating kinetics, enabling neurons to fire at very high rates (>100 Hz). These channels are strongly expressed in parvalbumin-positive interneurons, Purkinje cells, principal neurons of the auditory brainstem, and other fast-firing CNS cells. Kv3.2’s precise kinetics and gating properties are vital for maintaining rapid synaptic transmission, cortical inhibition, and neurologic functions underpinning learning, memory, and sensory processing. Disruption or mutation of Kv3.2—such as gain- or loss-of-function variants—can cause neurological diseases, most notably certain forms of epilepsy due to impaired GABAergic inhibition and developmental impairment. Molecularly, Kv3.2 channels are regulated by phosphorylation through kinases such as PKA and phosphatases like PP2A, affecting their open probability and current amplitude. Kv3.2 is a high-interest therapeutic target for interventions in epilepsy and possibly other brain disorders, though selectivity and safety remain ongoing challenges.
Blockade: Channel blockers (e.g., 4-aminopyridine) inhibit potassium efflux, prolonging action potentials. Allosteric modulation: Changes in phosphorylation state (PKA/PKG/PP2A) alter channel gating—enhancing or suppressing current. Disease-associated mutations (e.g., gain-of-function mutations Cys125Tyr) shift gating parameters and decrease firing rates of interneurons, leading to pathology like epilepsy.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Voltage-gated potassium channel subunit Kv3.2 (Kv3.2).